What are the standard modifiable cardiovascular risk factors (SMuRF) and how should each be managed?

Standard Modifiable Cardiovascular Risk Factors (SMuRF) and Management

The standard modifiable cardiovascular risk factors (SMuRF) comprise four key elements: hypertension, dyslipidemia, diabetes mellitus, and smoking—each requiring aggressive, evidence-based management to reduce cardiovascular morbidity and mortality. 1, 2

The Four SMuRF Components

1. Hypertension Management

Blood pressure should be lowered if ≥140/90 mm Hg with a treatment target of <130/80 mm Hg in most adults (<140/80 mm Hg in elderly patients). 3

• Hypertension is categorized as Stage 1 (130-139 mm Hg systolic or 80-89 mm Hg diastolic) or Stage 2 (≥140 mm Hg systolic or ≥90 mm Hg diastolic) 1
• First-line pharmacotherapy should include RAS inhibitors (ACE inhibitors or ARBs) combined with calcium channel blockers and/or thiazide-like diuretics 3
• Among U.S. adults with hypertension, 71% of those with diabetes also have hypertension, demonstrating the clustering of risk factors 1, 2

2. Dyslipidemia Management

LDL-cholesterol should be reduced according to cardiovascular risk profile: >50% reduction to <70 mg/dL (1.8 mmol/L) in patients with hypertension plus established CVD, CKD, diabetes, or high cardiovascular risk. 3

• Statin therapy is the cornerstone of lipid management and should be initiated in primary prevention if LDL-C >70 mg/dL in diabetes with target organ damage or >100 mg/dL in uncomplicated diabetes 3
• Among U.S. adults with hypertension between 2009-2012,63.2% had hypercholesterolemia 1
• Additional agents (ezetimibe, PCSK9 inhibitors) should be considered if targets are not achieved with statins alone 3

3. Diabetes Mellitus Management

Fasting serum glucose should be reduced below 126 mg/dL (7 mmol/L) or HbA1c below 7% (53 mmol/mol) in patients with diabetes. 3

• Among U.S. adults with hypertension, 27.2% had diabetes mellitus 1
• Treatment strategy should include RAS inhibitors as first-line agents, with CCBs and/or thiazide-like diuretics added as needed 3
• Comprehensive cardiovascular risk factor management is essential, as diabetes confers independent cardiovascular risk beyond other factors 4

4. Smoking Cessation

Smoking cessation is mandatory and should be actively addressed at every clinical encounter. 3

• Among U.S. adults with hypertension between 2009-2012,15.5% were current smokers 1
• Both active cigarette smoking and secondhand smoke exposure are modifiable risk factors requiring intervention 2
• Lifestyle changes including smoking cessation should be implemented regardless of other risk factor burden 3

Additional Modifiable Risk Factors

Beyond the core SMuRF components, several other modifiable factors require management:

Obesity and Physical Inactivity

• Among U.S. adults with hypertension, 49.5% were obese, and 35.7% of obese individuals had hypertension 1, 2
• Body weight control and regular physical activity are essential components of cardiovascular risk reduction 3, 2

Unhealthy Diet

• Dietary modification should be the first intervention for all patients, implemented for 3 months before reassessing need for pharmacotherapy 5
• Unhealthy diet patterns contribute to multiple cardiovascular risk factors through shared pathophysiologic mechanisms 1

Critical Clinical Considerations

Risk Factor Clustering and Synergy

The presence of multiple cardiovascular risk factors results in substantially higher absolute risk than single risk factors alone. 1

• Among U.S. adults with hypertension between 2009-2012,41.7% had a 10-year CHD risk >20%, while only 18.4% had risk <10% 1
• A meta-analysis of 257,384 patients demonstrated that lifetime risk of cardiovascular death, nonfatal MI, and stroke was substantially higher in adults with ≥2 risk factors compared to those with only one 1, 2

The SMuRF-less Paradox

Patients presenting with acute coronary syndrome without any SMuRFs (SMuRF-less) paradoxically have higher in-hospital mortality despite fewer traditional risk factors. 6, 7, 8

• SMuRF-less patients comprise approximately 11-12% of ACS presentations 6, 7
• These patients have 49-57% higher in-hospital mortality compared to those with SMuRFs (adjusted HR 1.35-1.57) 6, 7, 8
• Critically, guideline-directed medical therapy appears less effective in SMuRF-less patients (adjusted HR 0.98) compared to patients with SMuRFs (adjusted HR 0.80) 6
• SMuRF-less patients are significantly less likely to receive aspirin, antiplatelet therapy, beta-blockers, statins, and ACE inhibitors/ARBs at discharge 7, 8

Shared Pathophysiology

The relationship between hypertension and other modifiable risk factors is complex and interdependent, with several sharing mechanisms including:

• Overactivation of the renin-angiotensin-aldosterone system 1, 2
• Activation of the sympathetic nervous system 1, 2
• Inhibition of the cardiac natriuretic peptide system 1, 2
• Endothelial dysfunction 1, 2

Screening and Monitoring

Cardiovascular risk factors should be systematically assessed at least annually in all patients, with comprehensive screening before initiation of any potentially cardiotoxic therapies. 9, 4

• Clinical assessment should identify all known or potential risk factors including hypertension, diabetes, dyslipidemia, obesity, and smoking 9, 10
• Risk stratification tools (SCORE2, SCORE2-OP, or ASCVD risk calculator) should be used to estimate 10-year cardiovascular risk in appropriate populations 4, 11

Common Pitfalls

• Undertreatment of SMuRF-less patients: Despite worse outcomes, these patients receive less guideline-directed therapy—this represents a critical gap in care 6, 7, 8
• Failure to address multiple risk factors simultaneously: Treating individual risk factors in isolation misses the synergistic benefit of comprehensive risk factor modification 1
• Inadequate follow-up: Risk factors require ongoing monitoring and treatment adjustment, not one-time intervention 9